Centessa Pharmaceuticals Director's Share Option Cancellation Following Eli Lilly Acquisition

This Form 4 filing reports the cancellation of share options held by Centessa Pharmaceuticals director Mary Lynne Hedley following the company's acquisition by Eli Lilly. On June 24, 2026, Eli Lilly acquired all outstanding ordinary shares of Centessa Pharmaceuticals through a scheme of arrangement. As a result, all of Hedley's outstanding share options were automatically cancelled and converted into cash payments and contingent value rights. The filing details the cancellation of five separate option grants totaling 392,474 options with exercise prices ranging from $4.87 to $12.43 per share. Under the acquisition terms, each cancelled option entitled the holder to receive cash equal to the $38.00 acquisition price minus the exercise price, plus contingent value rights for potential additional payments up to $9.00 per share based on future milestones.